According to research, PSAT1, PSRC1, COLEC12, HP, and PLLP may play a role in small cell lung cancer metabolism, immune ...

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...

Shanghai Henlius Biotech, Inc. (2696.HK) announced that its anti-PD-1 mAb, HANSIZHUANG (serplulimab, marketed as Hetronifly® in Europe), has been officially approved by the European Commission (EC) ...

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “Acquired RUFY1-RET rearrangement as a ...

In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated ...

In the latest study, researchers found the main genetic mutations in renal cell cancer, possibly by using artificial intelligence (AI). The scientists injected mRNA vaccine made against proteins ...

Air pollution is the leading cause behind the rise in lung cancer cases among non-smokers, especially women and those living ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will respond to new therapies.

Table 1. Efficacy data from Phase II/III trials involving KRASG12C inhibitors sotorasib and adagrasib in pretreated advanced non-small cell lung cancer. Despite promising efficacy, resistance to ...

Imfinzi recommended for approval in European Union for the treat of adults with limited-stage small cell lung cancer ...